DJIA 17,947.92 -187.80 -1.04%
NASDAQ 4,948.74 -34.07 -0.68%
S&P 500 2,079.99 -21.05 -1.00%
market minute promo

CEL-SCI Corp (NYSEMKT: CVM)

1.04 -0.10 (-8.77%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

CVM $1.04 -8.77%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.14
Previous Close $1.14
Daily Range $1.04 - $1.14
52-Week Range $0.54 - $1.90
Market Cap $95.2M
P/E Ratio -2.53
Dividend (Yield) $0.00 (0.0%)
Volume 662,773
Average Daily Volume 812,074
Current FY EPS -$0.39

Sector

Healthcare

Industry

Drug Makers

CEL-SCI Corp (CVM) Description

The Company engages in the research and development of drugs and vaccines. Its most advanced product, Multikine, manufactured using the Company's proprietary cell culture technologies, is being developed for the treatment of cancer. Website: http://www.cel-sci.com/

News & Commentary Rss Feed

One Biotech Stock to Avoid

Our investing community's latest pick to avoid: Vical.

CEL-SCI Corporation (CVM) in Focus: Stock Jumps 5.6% - Tale of the Tape

CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head an

CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial

Cel-Sci Is Closer To The Finish Line, But Skip This Stock For Now

Pluristem Therapeutics: A Biotech Scam Promoted By A Bucket Shop

CEL-SCI Corp. (CVM) in Focus: Stock Adds 7.5% in Session - Tale of the Tape

CEL-SCI Receives Regulatory Clearance to Expand Its Phase III Head and Neck Cancer Trial into Romani

CEL-SCI Receives Regulatory Clearance to Expand Its Phase III Head and Neck Cancer Trial into Romania

CEL-SCI Quarterly Patient Enrollment In Its Head And Neck Cancer Phase III Trial Increases Eight Fol

CEL-SCI Quarterly Patient Enrollment In Its Head And Neck Cancer Phase III Trial Increases Eight Fold Over Same Prior Year Period

CEL-SCI Enrolls 22 Patients During October In Its Phase III Immunotherapy Head And Neck Cancer Trial

4 Stocks Under $10 Making Big Moves Higher

Wednesday Sector Leaders: Drugs, Biotechnology Stocks

See More CVM News...

CVM's Top Competitors

CVM $1.04 (-8.77%)
Current stock: CVM
AMGN $155.79 (-2.39%)
Current stock: AMGN
GILD $101.99 (-1.38%)
Current stock: GILD
BIIB $417.20 (-1.98%)
Current stock: BIIB